Research On The Synergy Effect Of Conba’s Acquisition Of Guizhou Baite

Pharmaceutical is a very important industry related to the national economy and the people’s livelihood.In recent years,the pharmaceutical industry has developed rapidly.However,it also faces some problems of low concentration of the industry and relatively serious homogenization of products.Through mergers and acquisitions,it is expected to achieve internal integration and enhance the competitiveness of enterprises.However,the complexity of M&A activities makes it a great risk.Failed cases occur frequently.A measure of the success of mergers and acquisitions in the theoretical community is whether synergies are obtained.The paper attempts to draw lessons from the analysis of synergies in the classic case of pharmaceutical mergers and acquisitions.This paper first uses the theoretical research method to expound the concept of corporate M&A and synergy,the development of China’s pharmaceutical industry and Conba M&A Case.Combining the research experience of other scholars and the characteristics of the pharmaceutical industry,the paper constructs an evaluation system of management synergy,business synergy and financial synergy.The analysis found that the merger did not achieve significant synergy.Finally,the enlightenment of the case is drawn.Enterprises should choose the appropriate M&A object.Payment means need to be optimized.Enterprises should pay attention to integration after mergers and acquisitions and the strength of endogenous growth.The paper is based on the individual case itself.Compared with a large number of case groups,the research conclusions are more targeted,and it will be a reference for the pharmaceutical companies that implement M&A in the future.